{"doi":"10.1101/2021.01.22.21250208","title":"Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C","abstract":"ABSTRACT Background The WHO has identified the need for a better understanding of which patients can be cured with ultrashort course hepatitis C (HCV) therapy Methods 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy (8 weeks) vs variable-duration ultrashort strategies (VUS1/2). Participants not cured following first-line treatment were retreated with 12 weeks’ sofosbuvir/ledipasvir/ribavirin. Primary outcome was sustained virological response 12 weeks (SVR12) after first-line treatment and retreatment. Participants were factorially randomised to receive ribavirin with first-line treatment. Results All evaluable participants achieved SVR12 overall (197/197, 100%[95%CI 98-100]) demonstrating non-inferiority between fixed-duration and variable-duration strategies (difference 0% [95%CI −3.8%,+3.7%], 4% pre-specified non-inferiority margin). First-line SVR12 was 91%[86%-97%] (92/101) for fixed-duration vs 48%[39%-57%] (47/98) for variable-duration, but was significantly higher for VUS2 (72% [56%-87%] (23/32)) than VUS1 (36% [25%-48%] (24/66)). Overall first-line SVR12 was 72%[65%-78%] (70/101) without ribavirin and 68%[61%-76%] (69/98) with ribavirin (p=0.48). At treatment failure, the emergence of viral resistance was lower with ribavirin (12% [2%-30%] (3/26)) than without (38% [21%-58%] (11/29), p=0.01). Conclusions Unsuccessful first-line short-course therapy did not compromise retreatment with sofosbuvir/ledipasvir/ribavirin (100% SVR12). SVR12 rates were significantly increased when ultrashort treatment varied between 4-7 weeks rather than 4-6 weeks. Ribavirin significantly reduced resistance emergence in those failing first-line therapy. Registration ISRCTN 37915093. Funding National Institutes of Health Research.","journal":"medRxiv","year":2021,"id":224169,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9493,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":647503,"name":"Sarah Pett","orcid":"0000-0002-4851-4727","position":1,"is_corresponding":false},{"id":783868,"name":"Leanne McCabe","orcid":"0000-0002-6509-8999","position":2,"is_corresponding":false},{"id":783869,"name":"Christopher R. Jones","orcid":"0000-0002-6301-2282","position":3,"is_corresponding":false},{"id":481429,"name":"Richard Gilson","orcid":"0000-0002-9572-193X","position":4,"is_corresponding":false},{"id":783870,"name":"Sumita Verma","orcid":"0000-0001-7021-8409","position":5,"is_corresponding":false},{"id":97721,"name":"Stephen Ryder","orcid":"0000-0001-9649-4444","position":6,"is_corresponding":false},{"id":97459,"name":"Jane Collier","orcid":null,"position":7,"is_corresponding":false},{"id":783871,"name":"Stephen T. Barclay","orcid":"0000-0003-0415-785X","position":8,"is_corresponding":false},{"id":97396,"name":"Aftab Ala","orcid":"0000-0001-6257-3160","position":9,"is_corresponding":false},{"id":664988,"name":"Sanjay Bhagani","orcid":"0000-0003-2557-4337","position":10,"is_corresponding":false},{"id":664989,"name":"Mark Nelson","orcid":"0000-0002-5944-6096","position":11,"is_corresponding":false},{"id":784373,"name":"Chinlye Ch’Ng","orcid":null,"position":12,"is_corresponding":false},{"id":784374,"name":"Ben Stone","orcid":null,"position":13,"is_corresponding":false},{"id":783872,"name":"Martin Wiselka","orcid":"0000-0002-4587-5826","position":14,"is_corresponding":false},{"id":97496,"name":"Daniel Forton","orcid":"0000-0002-0903-9169","position":15,"is_corresponding":false},{"id":783873,"name":"Stuart McPherson","orcid":"0000-0002-5638-2453","position":16,"is_corresponding":false},{"id":783874,"name":"Rachel Halford","orcid":"0000-0003-4569-2824","position":17,"is_corresponding":false},{"id":716541,"name":"Dung Nguyen","orcid":"0000-0001-9390-9990","position":18,"is_corresponding":false},{"id":783875,"name":"David A. Smith","orcid":"0000-0001-7778-7137","position":19,"is_corresponding":false},{"id":550375,"name":"M. Azim Ansari","orcid":"0000-0003-2790-8353","position":20,"is_corresponding":false},{"id":783876,"name":"Emily Dennis","orcid":"0000-0002-9634-7767","position":21,"is_corresponding":false},{"id":692058,"name":"Fleur Hudson","orcid":"0000-0001-5891-7514","position":22,"is_corresponding":false},{"id":106107,"name":"Eleanor Barnes","orcid":"0000-0002-0860-0831","position":23,"is_corresponding":false},{"id":245234,"name":"A. Sarah Walker","orcid":"0000-0002-0412-8509","position":24,"is_corresponding":false},{"id":775160,"name":"Graham Cooke","orcid":"0000-0001-6475-5056","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-18T23:54:18.470602Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}